Clinical Presentation and Treatment of High-Risk Sarcoidosis

被引:12
|
作者
Perlman, David M. [1 ]
Sudheendra, Muthya Tejasvini [1 ]
Furuya, Yuka [1 ]
Shenoy, Chetan [2 ]
Kalra, Rajat [2 ]
Roukoz, Henri [2 ]
Markowitz, Jeremy [2 ]
Maier, Lisa A. [3 ]
Bhargava, Maneesh [1 ]
机构
[1] Univ Minnesota, Dept Med, Sch Med, Div Pulm Allergy Crit Care & Sleep Med, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
[3] Natl Jewish Hlth, Div Environm & Occupat Hlth Sci, Denver, CO USA
关键词
high-risk sarcoidosis; cardiac sarcoidosis; progressive pulmonary sarcoidosis; neurosarcoidosis; multiorgan sarcoidosis; POSITRON-EMISSION-TOMOGRAPHY; LONG-TERM OUTCOMES; 6-MINUTE WALK TEST; PULMONARY SARCOIDOSIS; CARDIAC SARCOIDOSIS; CORTICOSTEROID-THERAPY; VENTRICULAR-ARRHYTHMIAS; MAGNETIC-RESONANCE; CNS SARCOIDOSIS; HYPERTENSION;
D O I
10.1513/AnnalsATS.202102-212CME
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Sarcoidosis is a multisystem disease of unknown cause with heterogeneous clinical manifestations and variable course. Spontaneous remissions occur in some patients, whereas others have progressive disease impacting survival, organ function, and quality of life. Four high-risk sarcoidosis phenotypes associated with chronic inflammation have recently been identified as highpriority areas for research. These include treatment-refractory pulmonary disease, cardiac sarcoidosis, neurosarcoidosis, and multiorgan sarcoidosis. Significant gaps currently exist in the understanding of these high-risk manifestations of sarcoidosis, including their natural history, diagnostic criteria, biomarkers, and the treatment strategy, such as the ideal agent, optimal dose, and treatment duration. The use of registries with well-phenotyped patients is a critical first step to study high-risk sarcoidosis manifestations systematically. We review the diagnostic and treatment approach to high-risk sarcoidosis manifestations. Appropriately identifying these disease subgroups will help enroll well-phenotyped patients in sarcoidosis registries and clinical trials, a necessary step to narrow existing gaps in understanding of this enigmatic disease.
引用
收藏
页码:1935 / 1947
页数:13
相关论文
共 50 条
  • [31] Gastrointestinal Sarcoidosis: A Rare Clinical Presentation
    Abdeljaleel, F.
    Nanah, A.
    Sadana, D. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [32] Sarcoidosis. Clinical presentation and prognosis
    Cavallasca, Javier A.
    Musuruana, Jorge L.
    MEDICINA-BUENOS AIRES, 2011, 71 (03) : 303 - 304
  • [33] A rare clinical presentation of sarcoidosis; gingivitis
    Guzel, Aygul
    Koksal, Nurhan
    Aydin, Davut
    Aslan, Kerim
    Goren, Fikret
    Karagoz, Filiz
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2013, 116 (04): : E280 - E282
  • [34] Sarcoidosis - A Clinical Case with Neuropsychiatric Presentation
    Baptista, Ana Margarida
    Mateiro, Rita
    Moutinho, Adriana
    Alves, Rute
    PSILOGOS, 2012, 10 (01) : 19 - 22
  • [35] TREATMENT OF HIGH-RISK HYPERTENSION IN 1989
    PLOIN, M
    GAZETTE MEDICALE, 1989, 96 (25): : 59 - 59
  • [36] Treatment of high-risk myelodysplastic syndromes
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 12 - 13
  • [37] Treatment of High-Risk Chronic GVHD
    Pavletic, Steven
    Vogelsand, Georgia B.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (12) : 1436 - 1437
  • [38] TREATMENT STRATEGIES FOR HIGH-RISK LEUKEMIA
    HENDERSON, ES
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (05) : 689 - 691
  • [39] Treatment of high-risk smoldering myeloma
    Korde, Neha
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 695 - 696
  • [40] Adjuvant treatment of high-risk melanoma
    Simon S.C.S.
    Utikal J.
    best practice onkologie, 2021, 16 (7-8) : 308 - 314